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Advances in digital health and novel diagnostics for sexually transmitted infections (STIs) and HIV 
have created new opportunities for people to access information, testing and, in some cases, 
treatment remote from traditional healthcare settings. 
Legislation and regulation can facilitate or impede innovation in service delivery. For example, the 
Health and Social Care Act of 2012 moved responsibility for public health, including the majority of 
sexual health services, from the NHS to local government. Shifts in commissioning and service 
delivery have occurred, with major disinvestment in sexual health services, which has led to 
innovative models of care being introduced, including online services [1].  
There is an underlying but un-evidenced assumption that online sexual health services will preserve 
access and increase uptake at a reduced cost. This has led many services to introduce or expand 
their online presence, which ranges from simple unidirectional health promotion to more ambitious 
self-sampling services which aim to ‘channel shift’ those without symptoms away from face-to-face 
services and into online care.  
All healthcare professionals, healthcare services, and the medicines and devices they use are 
regulated, whether care is ‘traditional’ or remote, including online. Most regulations were 
established in the pre-digital era, although many professional bodies in the UK have adapted their 
existing guidance to incorporate online services. There are three key areas of regulation which are 
particularly relevant to online care:   
(i) Safety of prescribing: In 2013, the General Medical Council (GMC) published pragmatic 
advice on prescribing for patients who are assessed via remote consultation, including 
online[2].  
(ii) Quality of care: Online services should be registered with the Care Quality Commission 
(CQC) and are subject to review using the same five criteria as other health and social 
care services (services should be safe, effective, caring, responsive to people’s needs, 
and well-led). 
(iii) Regulation of technology: if an online system involves a level of automation in 
diagnosis, prevention, monitoring, or treatment, or involves a component that is 
interpreting a test result, it is classified as an active “medical device” or an in vitro 
diagnostic device, which require registration with the  Medicines and Healthcare 
products Regulatory Agency (MHRA) and CE marking [3].   
Despite these clarifications to the guidance, a number of areas of uncertainty remain.  
Open access: Legislation requires sexual health services in England to be provided open access, 
therefore local authorities must provide services to all people living within that area[4] without the 
need for GP referral. The effect of initial triage only being offered online on people who do not have 
easy, private access to the internet, or who are unable to navigate this service due to language 
barriers, mental capacity, or lack of digital literacy is not yet known and requires further monitoring.   
Safeguarding: Access to sexual health services does not require proof of identity and services are 
often used by under-18s. This creates a tension for online services which must balance the need to 
safeguard potentially-vulnerable patients with maintaining confidentiality and removing barriers to 
care. The CQC has already raised concerns about identifying those under 18 in a report on one 
positively-rated online testing service (SH-24)[5].  
Remote diagnosis and prescribing: There is preliminary evidence that uncomplicated chlamydia can 
be managed completely remotely, with provision of results followed by an automated online 
consultation, and automated prescribing[6]. However, electronic prescriptions may currently only be 
sent to community pharmacies via the Electronic Prescribing Service (EPS)[7], which requires sharing 
personal identifiable data including NHS number, not usually collected by sexual health services.   
Data Protection and Confidentiality: Following changes to legislation around confidentiality of 
sexual health services in England, it is now possible for services to use personal identifiers (i.e. NHS 
numbers), although this is not routine practice[8]. Given the above challenges, there may be 
advantages of an online service collecting sufficient personal data to allow linkage to NHS number, 
with consent, to verify age and to allow use of the EPS. However, concerns related to security of 
online information, how data collected online is being used[9], and fears that people will not access 
these services if they perceive them to be less confidential, are pertinent.   
Internationally, data protection and privacy laws have changed dramatically over the past 20 years, 
reflecting the developments in digital technology that have occurred over this time, and the need to 
develop flexible laws that accommodate  unforeseen developments in the future[10]. The new 
European General Data Protection Regulation (GDPR), which was implemented in May 2018, is the 
most far-reaching and wide-ranging legislation in existence[10]. It strengthens data subjects’ rights, 
requires openness and transparency, and has specific requirements for automated decision making 
systems[10][11]. For example, Article 22(1) states that “the data subject shall have the right not to 
be subject to a decision based solely on automated processing, including profiling, which produces 
legal effects concerning him or her or similarly significantly affects him or her”[11]. If sexual health 
services move to purely automated online triage systems, then some of the conditions that will need 
to be in place include provision of information about the processing, and methods for an individual 
to easily access human intervention or challenge a decision[11]. 
Other changes to legislative framework: Although published in 2017, the provisions within the 
medical device regulations and in vitro diagnostic regulations are being implemented over a 
“transition period” and only come fully into force in 2020 and 2022 respectively[3].  At present, 
there is uncertainty as to what will happen with such provisions  that have not been fully 
implemented on the date that Brexit occurs[12].  
The UK is seeing an era of rapid transition of sexual health services in which online service provision 
is centre stage. While it is now technically feasible to deliver comprehensive online Sexual Health 
services, much of the shift in delivery has happened before a number of legal and regulatory issues 
have been elucidated, and adapted where necessary. We need a cohesive, multi-agency approach to 
addressing these challenges if we are to harness the potential for online sexual health services whilst 
safeguarding the most vulnerable and remaining true to the founding principles of sexual health 
care.  
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